COMPARE · Reviewed July 17, 2026
ADMA vs VEEV
Verdict: Side-by-side breakdown using the Bull Rankings model. ADMA scored 84.6, VEEV scored 82.4 — ADMA leads.
Compare another set
ADMA
ADMA Biologics, Inc.
84.6
$8.71 · $2.0B
Score gap
2.2
ADMA leads
VEEV
Veeva Systems Inc.
82.4
$195.38 · $31.7B
The model, pillar by pillar (0–100 each)
ADMA
stronger →← stronger
VEEV
81
Qualityreturns · margins · balance sheet
77
90
Growthrevenue & earnings expansion
94
83
Valuevaluation vs sector peers
77
ADMA is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
ADMA
VEEV
$108mC
FCF
$1.7bC+
+11.0%B
Rev
+16.2%B+
1.11C
D/E
0.01A-
12.8xA
P/E
34.6xC+
0.65A-
PEG
0.87B+
Winner per row is the stronger grade in our model; a tie or a missing value shows no highlight.
Valuation · DCF cross-check
ADMA
VEEV
36% below
Price vs fair valuelower is cheaper
4% above
~3%/yr
Growth the price implies10-yr FCF · lower = less priced in
~8%/yr
+20%
1-yr DCF upside
-13%
+56%
5-yr DCF upside
-4%
+132%
10-yr DCF upside
+11%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
ADMA
Why this score
- Buying back stock
- Durable high returns
- Earnings outpace cash
VEEV
No notable signals flagged.
The companies
ADMAADMA Biologics, Inc.
Why now
Biotechnology · market cap $2.0b. Down 57% from 52-week high of $20.46 — deep drawdown territory. Revenue growing +11%, comfortably above the S&P median. PEG 0.65 — paying under fair value for the growth rate. 5 sell-side analysts rate this a Buy with a mean 1-yr target of $17.00 (implying +95% upside).
Moat
Net margin 32% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 42% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Down 57% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
VEEVVeeva Systems Inc.
Why now
Health Information Services · market cap $31.7b. Down 37% from 52-week high of $310.50 — deep drawdown territory. Revenue growing +16%, comfortably above the S&P median. PEG 0.87 — paying under fair value for the growth rate. 27 sell-side analysts rate this a Buy with a mean 1-yr target of $244.59 (implying +25% upside).
Moat
Net margin 28% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 13% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. FCF converts 177% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Down 37% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Trailing P/E 35x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.